Lip GYH - Search Results

1

Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study.

Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Fusco MD, Garcia Reeves AB, Yuce H, Lip GYH. Deitelzweig S, et al. Among authors: lip gyh. J Clin Med. 2020 May 28;9(6):1633. doi: 10.3390/jcm9061633. J Clin Med. 2020. PMID: 32481607 Free PMC article.

2

Novel oral anticoagulants.

Khoo CW, Tay KH, Shantsila E, Lip GY. Khoo CW, et al. Int J Clin Pract. 2009 Apr;63(4):630-41. doi: 10.1111/j.1742-1241.2009.02011.x. Epub 2009 Feb 16. Int J Clin Pract. 2009. PMID: 19222611 Review.

3

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P. Lip GY, et al. Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6. Clin Ther. 2014. PMID: 24508420 Free article.

4

Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?

Dzeshka MS, Lip GY. Dzeshka MS, et al. Trends Cardiovasc Med. 2015 May;25(4):315-36. doi: 10.1016/j.tcm.2014.10.017. Epub 2014 Oct 30. Trends Cardiovasc Med. 2015. PMID: 25440108 Review.

5

Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.

Lee SI, Sayers M, Lip GY, Lane DA. Lee SI, et al. Int J Clin Pract. 2015 Nov;69(11):1341-8. doi: 10.1111/ijcp.12712. Epub 2015 Aug 3. Int J Clin Pract. 2015. PMID: 26234557

6

Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.

Lip GY, Lanitis T, Mardekian J, Kongnakorn T, Phatak H, Dorian P. Lip GY, et al. Stroke. 2015 Oct;46(10):2830-7. doi: 10.1161/STROKEAHA.115.009995. Epub 2015 Aug 27. Stroke. 2015. PMID: 26316345 Clinical Trial.

7

Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Larsen TB, et al. BMJ. 2016 Jun 16;353:i3189. doi: 10.1136/bmj.i3189. BMJ. 2016. PMID: 27312796 Free PMC article.

8

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.

Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Lip GY, et al. Thromb Haemost. 2016 Oct 28;116(5):975-986. doi: 10.1160/TH16-05-0403. Epub 2016 Aug 19. Thromb Haemost. 2016. PMID: 27538358

9

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.

Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, Bruno A, Phatak H. Lip GY, et al. Int J Clin Pract. 2016 Sep;70(9):752-63. doi: 10.1111/ijcp.12863. Epub 2016 Aug 23. Int J Clin Pract. 2016. PMID: 27550177 Free PMC article.

10

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Nielsen PB, et al. BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510. BMJ. 2017. PMID: 28188243 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,609 results

Search Page

Filters